Answers are grounded in this paper and cite their sources.
Neuroinflammatory disorders, such as Alzheimer’s disease (AD) and multiple sclerosis (MS), are increasingly recognized as systemic inflammatory syndromes rather than isolated brain pathologies. A central regulator of this systemic response is the microbiota–gut–brain axis (MGBA), where dysbiosis‐induced disruption accelerates neuroinflammation and compromises blood‐brain barrier (BBB) integrity. Plant‐derived compounds (PDCs) offer a promising multitarget approach for these complex disorders; however, their clinical translation is frequently hindered by poor bioavailability and chemical complexity. This review evaluates how computational methods facilitate the discovery of PDCs that modulate the MGBA. Network pharmacology maps the interactions between these compounds and multiple molecular targets involved in inflammation and gut homeostasis. Furthermore, molecular docking and molecular dynamics simulations characterize the binding affinity and structural stability of these interactions. In silico ADMET models are additionally employed to predict pharmacokinetic profiles, safety, and BBB permeability. Together, these approaches provide a robust, time‐efficient strategy to identify natural therapies, including bioactive microbial metabolites that bypass traditional bioavailability constraints. Future integration of artificial intelligence (AI) and multiomics holds the potential to further decode the synergistic interactions between PDCs and the gut microbiome, paving the way for personalized neuroprotective strategies.
No takes yet. Share an insight, caveat, or question.
Purhematy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: